Shaping the Future of Cancer Immunotherapy Through Multispecific Innovation

Cancer treatment is evolving toward approaches that combine multiple targets and mechanisms to improve therapeutic outcomes. By integrating complementary functions within a single molecule, multispecific antibodies offer new possibilities for addressing the complexity of cancer and resistance to treatment.

At Y-Biologics, we combine proprietary antibody discovery and engineering technologies with a deep understanding of immunobiology to develop differentiated multispecific antibody-based therapeutics. Our research spans a 'Multi-AbKine' platform, which integrates multispecific antibodies with cytokines, and an expanding range of strategies that bring together diverse targets and functions to address the limitations of current cancer immunotherapies.

Our goal is to translate scientific innovation into meaningful treatment opportunities for patients. Through precise molecular design, rigorous preclinical and clinical development, and global partnerships, we aim to deliver deeper and more durable treatment responses—and become a global leader in next-generation cancer immunotherapy.